Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

AI Briefing

• – Enrollment in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis continues to progress.
• – Descartes-08 shows promise in treating myasthenia gravis, with positive results from early-stage clinical trials.
• – Company to provide additional updates on AURORA trial and other business developments in the coming months.